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Abstract Six charged amino acid residues located in the
ectodomain of the full-length type I transforming growth factor
(TGF)-L receptor were individually mutated to alanine. Mutation
of residues D47, D98, K102 and E104 resulted in functionally
impaired receptors as demonstrated by a marked decrease in
ligand-dependent signaling and ligand internalization relative to
the wild-type receptor. The other two mutants (K39A and K87A)
exhibited wild-type-like activity. Molecular modeling indicates
that the four functionally important residues are located on the
convex face of the ectodomain structure. Since mutation of these
four residues affects signaling and ligand internalization but not
ligand binding, we propose that this functional site is an
interacting site between type I and II receptors. ß 2002 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
The transforming growth factor-L (TGF-L) superfamily of
proteins are key regulators of a wide variety of cellular pro-
cesses including cell proliferation, di¡erentiation, extracellular
matrix deposition and development [1^4]. The signaling events
initiated by these growth factors are mediated through two
transmembrane receptors that possess serine/threonine kinase
activity [5]. It has been established that TGF-L, a 25 kDa
dimer, binds to the type II TGF-L receptor (TLRII) which
then phosphorylates the type I TGF-L receptor (TLRI) [6,7].
This phosphorylation event activates TLRI, the major signal-
ing receptor, which can then trigger several signaling path-
ways by activating downstream targets such as the Smad fam-
ily of proteins [8^10].
Two models have been proposed for the mechanism of
formation and activation of the heteromeric TGF-L/TLRII/
TLRI ligand^receptor complex. The ¢rst model involves bind-
ing of the TGF-L ligand to the type II TGF-L receptor ecto-
domain (TLRII-ECD) which then recruits the type I TGF-L
receptor ectodomain (TLRI-ECD) to form an active ligand^
receptor complex [6,7]. A second more recent model proposes
that TLRI and TLRII form an inactive receptor complex in
the absence of ligand and that TGF-L binding induces a rel-
ative reorientation of TLRI-ECD and TLRII-ECD that allows
productive alignment of the intracellular kinase domains of
the two receptors [11,12]. Thus, it is clear that the ectodo-
mains of TLRI and TLRII play an important role in modu-
lating TGF-L signaling. However, the speci¢c amino acid res-
idues involved in the underlying intermolecular interactions
within the TGF-L/TLRII-ECD/TLRI-ECD complex are pres-
ently unknown due to the lack of relevant structural and func-
tional data.
In this study, TLRI was subjected to alanine point muta-
genesis in order to identify functional amino acid residues on
its ectodomain. Six charged residues located in the TLRI-ECD
were individually mutated to alanine. Targeting of charged
residues was motivated, ¢rstly, by a reduced susceptibility to
global alteration of the domain structure upon mutation since
charged side chains are often exposed to the solvent at the
protein surface. Secondly, it is widely accepted that electro-
static interactions are important for molecular binding and
recognition. Analysis of atomic resolution structures has
shown that protein^protein interfaces are rich in polar and
charged side chains that generally participate in hydrogen
bond interactions [13]. Currently, there is a growing consensus
that electrostatic interactions are likely to enhance binding
speci¢city although they do not necessarily contribute strongly
to binding a⁄nity [14^20].
We ¢rst characterized the TLRI mutants for their level of
expression at the cell surface as well as for the e⁄ciency of
their a⁄nity cross-linking to the TGF-L1 ligand in the pres-
ence of TLRII. The functional competency of mutant TLRIs
was assessed independently in ligand-induced signaling and
ligand endocytosis experiments. One of the six point muta-
tions to alanine altered signi¢cantly the TLRI/ligand cross-
linking e⁄ciency. Four of the six mutants displayed marked
reductions in ligand-dependent signaling as well as in the level
of ligand internalization. The three-dimensional structure of
the TLRI-ECD was modeled based on the recently determined
crystal structure of the homologous type IA bone morphoge-
netic protein receptor ectodomain (BRIA-ECD) in complex
with the bone morphogenetic protein 2 (BMP-2) ligand [21].
The TLRI-ECD model is used as a framework for structural
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and mechanistic interpretation of the data resulting from this
¢rst functional mutagenesis investigation of the ectodomain of
TLRI.
2. Materials and methods
2.1. Plasmids and mutagenesis
The full-length rat TGF-L receptor type I cDNA (GenBank acces-
sion number L26110) was subcloned at the EcoRI site of pcDNA-3
(Invitrogen) to yield p3TLR1. A 1.1-kbp KpnI fragment was further
subcloned in pBluescript SK (Stratagene) to produce pBTLR1K. An
N-terminal 6UHis tag was added by ligating a double stranded oli-
gonucleotide (5P-TGGACATCACCACCATCATCACGC) at the
SmaI site (position 113) just after the signal peptide. This plasmid
was then used as a template for site directed mutagenesis according
to Barettino et al. [22]. The anchor-T7 primer is 5P-GACTCGAGTC-
GACATCGTAATACGACTCACTATAGGG; the anchor speci¢c
primer corresponds to the ¢rst 17 bases of the former primer. Muta-
genic primers complementary to the coding strand were as follows
(mutated bases are underlined): K39A = 5P-AAAATTGTCCGCTGT-
ACAGAGG, K47A = 5P-GCAGAGACCAGCTGTCTCAC, K87A =
5P-GCCCCTGTTGCTGAAGATGG, D98A = 5P-TGCAGTGAGC-
CTGATTGC, K102A = 5P-GGGAGTTCTATTGCATTGCAGTG,
E104A = 5P-AGTTGGGAGTGCTATTTTAT.
Ampli¢cation products were puri¢ed (Qiaquick-PCR, Qiagen), and
cloned in the pBTLR1K plasmid as a 325 bp NcoI^PpuMI fragment
using standard procedures. Clones that contained mutations were se-
lected by dideoxy sequencing (Pharmacia), and subcloned back into
the original expression plasmid (p3TLR1) as KpnI fragments.
2.2. Cell culture and transfections
HEK 293 cells, and Mink Lung Epithelial R1-B/L-17 cells were
maintained in Dulbecco’s modi¢ed Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS). 293 cells were seeded in
12 well plates (1U105 cells/well) or 60 mm dishes (4U105 cells/well)
and transfected with SuperFect transfection reagent (Qiagen) accord-
ing to the manufacturer’s protocol. R1-B cells were seeded in 60 mm
dishes (4U105 cells/well) and also transfected with SuperFect reagent.
After 3 h of incubation, the transfection reagent was removed and
replaced with fresh complete media.
2.3. Surface expression
293 cells were transfected using 2 Wg of DNA and 5 Wl of SuperFect
reagent according to the manufacturer’s protocol. 48 h after trans-
fection the cells were suspended in cold DMEM-10% FBS for 30 min
on ice and then incubated 1 h on ice in the presence of an anti-6UHis
monoclonal antibody (Clontech) diluted 1:1000. After a wash in cold
DMEM-10% FBS, cells were incubated 1 h on ice with a FITC con-
jugate Goat anti-mouse FcQ fragment speci¢c IgG (Jackson) diluted
1:100. Cells were then washed in cold DMEM-10% FBS and analyzed
by £ow cytometry on an EPIC0 XL^MCS (Beckman/Coulter0).
2.4. A⁄nity cross-linking
[125I]TGF-L1 was purchased from NEN Life Sciences Products. 293
cells were transfected with 1.5 Wg of DNA at a 1:1 ratio of wild-type
or mutant TLRI DNA to wild-type TLRII DNA using SuperFect
reagent (Qiagen). 48 h after transfection the cells were incubated
with 150 pM of [125I]TGF-L1 on ice for 3 h and receptor-bound ligand
was cross-linked with BS3 (Pierce) as previously described [23]. La-
beled receptors were then solubilized in 1% Triton X-100, 10% glyc-
erol, 20 mM Tris pH 7.4, 1 mM EDTA. Iodinated ligand^receptor
complexes were resolved on 4^12% gradient SDS^PAGE, and the gel
¢xed in methanol^acetic acid, dried and exposed on a phosphorimager
screen.
2.5. Signaling assay
R1-B cells were cotransfected with wild-type or mutant TLRI DNA,
luciferase reporter DNA (p3TP-Lux) and green £uorescent protein
DNA (GFPq, Quantum Biotechnology) to normalize for transfection
e⁄ciency. After transfection, the cells were split in two aliquots. The
¢rst aliquot was used for the signaling assay. 24 h after transfection,
the cells were incubated 3 h in serum-free medium, then treated or not
with 150 pM of TGF-L1 (RpD Systems) for 16 h. Cells were then
lysed in 100 Wl of cell culture lysis reagent and 20 Wl aliquots were
used to measure luciferase activity (Promega, luciferase assay system)
on a Lumat LB9501 (Berthold) for 20 s. A DNA ratio of 2:9:1 for
TLRI:p3TP-lux:GFPq was used. The second aliquot was analyzed by
£ow cytometry on an EPICS0 XL-MCS (Beckman/Coulter0) and the
total £uorescence value was used to normalize for transfection e⁄-
ciency.
2.6. Ligand internalization assay
293 cells were transfected with the plasmids expressing wild-type or
mutant TLRI and wild-type TLRII using SuperFect reagent (Qiagen)
according to the manufacturer’s speci¢cations. After 20 h the cells
were tested for internalization of [125I]TGF-L1. Cells were washed
twice with TGF-L binding media (200 mM HEPES-bu¡ered
DMEM pH 7.4, 0.2% bovine serum albumin (BSA)) and then incu-
bated in binding media for 30 min at 4‡C. Cells were then treated with
100 pM [125I]TGF-L1 in cold binding media plus or minus unlabeled
10 nM TGF-L1 and immediately transferred to a 37‡C water bath for
90 min. Control time course assays indicated that the amount of
TGF-L1 internalized was maximal within this time period (data not
shown). Cells were then transferred on ice and washed twice with
Dulbecco’s phosphate-bu¡ered saline containing 0.9 mM CaCl2, 0.5
mM MgCl2 (D-PBS2) and 0.1% BSA. Surface ligand was removed
from the cells by washing twice with 150 mM NaCl, 0.1% acetic acid
at 4‡C for 2 min each. Internalized ligand was then extracted in
solubilization bu¡er (1.0% Triton-X-100, 10% glycerol, 1 mM
EDTA, 20 mM Tris^HCl pH 7.5) for 30 min at 4‡C. The amount
of internalized ligand was quanti¢ed in a gamma counter. Speci¢c
counts (speci¢c cpm) were determined by subtracting competed sam-
ples (plus unlabeled TGF-L1) from non-competed samples.
2.7. Statistics
Data were analyzed by one-way analysis of variance using Ps 0.05
as signi¢cance criterion. Post-hoc analysis relied on Dunnet’s Multiple
Comparison Test using the Prism software (GraphPad Software Inc.).
2.8. Molecular modeling
The three-dimensional structure of human TLRI-ECD (residues
G30^P119) was predicted by combining homology modeling with con-
formational sampling. Homology modeling was carried out using the
program COMPOSER [24] implemented in SYBYL 6.6 molecular
modeling software (Tripos). The 2.9 Aî resolution crystal structure
of type IA bone morphogenetic protein receptor ectodomain
(BRIA-ECD) determined in complex with the BMP-2 ligand [21]
(PDB entry 1ES7) was used as a template. The conserved pattern of
10 cysteine residues in the target/template sequence alignment (Fig. 1)
allowed formation of ¢ve disul¢de bonds in TLRI-ECD based on the
disul¢de connectivity observed in BRIA-ECD structure. Five structur-
ally conserved regions (SCRs) and four intervening structurally vari-
able regions (SVRs, i.e. loops with di¡erent length in TLRI-ECD and
BRIA-ECD) were assigned in order to build a preliminary model of
TLRI-ECD (Fig. 1). An initial conformation for each SVR was con-
structed by searching a database of protein structures deposited in
PDB. Structural re¢nement was done by energy minimization in SYB-
YL 6.6 using the AMBER 4.1 all-atom force ¢eld [25] with the Powel
minimizer, a distance-dependent (4R) dielectric constant, an 8 Aî non-
bonded cuto¡, and a root mean square di¡erence (RMSD) gradient of
0.05 kcal/mol Aî (these settings were also used in the conformational
search re¢nement stage, see below). Sequential energy minimization
runs were carried out in order to allow a gradual relaxation of the
structure, starting with SVRs, then including the side chains of SCRs,
and ¢nally energy minimizing the entire structure.
The SVRs in the resulting TLRI-ECD model were re¢ned by con-
formational search using the Monte Carlo minimization (MCM) ap-
proach [26^29]. The sampling region (SR) was composed of the loops
H39^F46 (SR-I), T61^K64 (SR-II) and E74^R82 (SR-III), thus cover-
ing all SVRs (Fig. 1). In each MCM cycle, a starting conformation of
the protein was generated by randomly perturbing one or more dihe-
dral angles in the SR. These perturbations involved random changes
in the side chain dihedral angles and crankshaft rotations around the
peptide units. Disul¢de bonds as well as the C-terminal peptide bond
at each of the three sampled loops were broken prior to backbone
dihedral angle rotations and re-formed for energy minimization. The
starting conformation then was subjected to an AMBER 4.1 energy
minimization in which only the backbone atoms of the residues form-
ing the L-sheets of the domain, (which belong to the SCRs) were kept
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rigid. The decision of accepting or rejecting the resulting conforma-
tion was taken on energy basis according to the Metropolis proba-
bility criterion. An accepted conformation or a rejected conformation
whose internal energy was within 10 kcal/mol above the internal en-
ergy of the current accepted conformation was stored in a database
after passing through the chirality and RMSD-based conformer re-
dundancy ¢lters. A total of 30 000 MCM cycles were carried out to
generate a database of energy-ranked feasible conformations of the
domain structure. The quality of the TLRI-ECD model corresponding
to the lowest energy conformation was assessed with the PRO-
CHECK program [30] and the PROTABLE module in SYBYL 6.6.
3. Results and discussion
3.1. Expression of mutant TLRIs and formation of mutant
TLRI/TLRII complexes
The surface expression of wild-type and mutant TLRIs was
monitored by £ow cytometry in transiently transfected 293
cells using an antibody directed against a 6UHis tag added
to the N-terminus of each receptor. Expression of mutant
TLRIs varied between 82% and 91% relative to wild-type
TLRI (Fig. 2). TLRI forms a heteromeric receptor complex
with TLRII and can be a⁄nity cross-linked to the ligand only
in the presence of TLRII. Therefore, ligand binding properties
of the wild-type and mutant TLRIs were investigated in order
to assess the formation of mutant TLRI/TLRII complexes.
Each TLRI was cotransfected with wild-type TLRII in 293
cells followed by a⁄nity cross-linking to 150 pM of
[125I]TGF-L1. With one exception, all mutant TLRIs were
found to be crossed-linked to ligand in the presence of wild-
type TLRII at levels comparable to that of the wild-type TLRI
(Fig. 3). One mutant, K87A, was a⁄nity cross-linked with
lower e⁄ciency (59% relative to the wild-type). The reduced
labeling of this mutant is likely due to the loss of a free amino
group that may be required for covalent cross-linking. These
results indicate that the mutant TLRIs are e⁄ciently expressed
and transported to the cell surface, bind the TGF-L ligand,
and form heteromeric receptor complexes in the presence of
the ligand.
3.2. Ligand-dependent signaling of mutant TLRI/TLRII
complexes
Although receptor heteromerization is necessary for TGF-L
signaling, optimal activity also requires formation of a func-
tional heteromeric receptor complex characterized by the cor-
Fig. 1. Sequence alignment used in the modeling of the human TLRI-ECD structure. Secondary structural elements observed in the crystal
structure of the BRIA-ECD template are shown and labeled. Cysteine residues are highlighted in yellow. Structurally conserved regions (SCRs)
assigned in the initial model building are enclosed in boxes. Non-homologous loops of TLRI-ECD included in the MCM sampling region (SR)
are highlighted on red background and labeled SR-I to III. The sequence of rat TLRI-ECD, used in our experiments, is also aligned, with the
residues that were mutated to alanine highlighted on blue background, and with the residues that are di¡erent in the human TLRI-ECD se-
quence indicated in bold. The position of a four amino acid insertion in the rat sequence is also shown.
Fig. 2. Surface expression of TLRI mutants. Transiently transfected
293 cells were incubated with an antibody directed against the N-
terminal 6UHis tag on TLRI and detected by £ow cytometry analy-
sis with an FITC-conjugated secondary antibody (see Section 2).
Histograms show the mean £uorescence values calculated from four
independent experiments.
Fig. 3. A⁄nity cross-linking of TLRI mutants. 293 cells were transi-
ently transfected with TLRII without TLRI or together with wild-
type or mutant TLRIs followed by cross-linking to [I125]TGF-L1.
Labeled receptors were resolved on 4^12% gradient gels and ex-
posed to phosphorimager screens. Mutants are labeled in the respec-
tive lanes. M: molecular weight (kDa).
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rect alignment of the TLRI and TLRII ectodomains [11,12].
Therefore, wild-type and mutant TLRIs were analyzed for
their ability to rescue TGF-L-dependent signaling in Mink
Lung Epithelial R1-B/L-17 cells. This cell line lacks cell sur-
face TLRI and therefore TGF-L responsiveness. A reporter
plasmid, p3TP-Lux, which contains three copies of the plas-
minogen activator inhibitor-1 promoter (PAI-1) upstream to
the luciferase gene, was cotransfected with wild-type or each
mutant TLRI and cell responsiveness was assayed by measur-
ing TGF-L-induced luciferase activity [5]. The results show
that none of the mutant TLRIs was entirely defective in sig-
naling. However, their signaling capability varied signi¢cantly
(Fig. 4). The D98A mutant signaled at the lowest level (30%
of wild-type activity), whereas mutants D47A, K102A and
E104A retained only 40^60% of the wild-type TLRI activity.
In contrast, mutants K39A and K87A were able to rescue
signaling at levels comparable to that of the wild-type recep-
tor. These results indicate that, although all mutant TLRIs
were able to form heteromeric complexes with TLRII in the
presence of the ligand, the stability of the productive TLRI/
TLRII complex was reduced upon D98A, D47A, K102A and
E104A mutations, but remained una¡ected by the K39A and
K87A mutations introduced in the TLRI-ECD. The observa-
tion that mutant K87A, which was cross-linked with lower
Fig. 4. Signaling by the TLRI mutants. Mink Lung Epithelial R1-B/
L-17 cells were transiently cotransfected with a luciferase reporter
plasmid and wild-type or mutant TLRIs. Histograms show the level
of luciferase activity expressed as percent of wild-type TLRI activity.
Data are the mean values obtained from three di¡erent experiments.
White bars show the signaling of non-treated cells and gray bars
the signaling of TGF-L1-treated cells.
Fig. 5. Internalization of ligand by TLRI mutants. Transiently
transfected 293 cells were incubated with [I125]TGF-L1 in the pres-
ence (competed) or absence of 100 fold excess of unlabeled TGF-
L1. After removing surface-bound ligand, the speci¢c counts from
internalized ligand were calculated by subtracting competed samples
from total counts (non-competed). Data were obtained from at least
three independent experiments and are expressed as percent of wild-
type TLRI ligand internalization.
Fig. 6. Stereoview of the structural mapping of the TLRI functional site. The human TLRI-ECD model structure (black tube) and BRIA-ECD
crystal structure (yellow tube) are overlaid, with the convex side in front. The structures superimpose with an RMSD of 0.59 Aî between the
corresponding CK atoms of the ¢ve structurally conserved L-strands. MCM-sampled regions (SRs) of TLRI-ECD are labeled (see also Fig. 1).
The side chains (including CK atoms) of TLRI residues mutated to alanine are shown as CPK models and labeled according to the rat TLRI
sequence. The side chains delineating a functional, TLRII-ECD interacting site of TLRI-ECD are shown with orange carbon atoms. The func-
tionally irrelevant side chains are shown with cyan carbon atoms. The Connolly surface of the BMP-2 ligand is displayed relative to the super-
imposed ectodomains, based on the orientation observed in the crystal structure of the BRIA-ECD/BMP-2 complex. There was no attempt to
optimize the interactions in the TLRI-ECD/BMP-2 complex. The tip of the hairpin L7^L8 of the BMP-2 ligand is indicated, in order to high-
light the corresponding relative location of a functional, TLRII-ECD interacting site of the TGF-L ligand.
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e⁄ciency, rescued signaling at wild-type receptor levels, sup-
ports the idea that reduced labeling of this mutant results
from less e⁄cient cross-linking rather than a disruption of
the heteromeric TLRI/TLRII/ligand complex.
3.3. Ligand internalization by mutant TLRI/TLRII complexes
Using chimeric [31] and wild-type [32] receptors, it has been
shown that ligand internalization is optimal when both TLRI
and TLRII are coexpressed. Using chimeric receptors it was
also shown that the kinase activity of TLRII, but not TLRI, is
essential for maximal ligand internalization by the heteromer-
ic receptor complex [31]. These experiments indicate that a
ligand internalization assay may be used as an indicator of
TLRI/TLRII complex formation, in addition to the a⁄nity
cross-linking and signaling assays. Therefore, we employed a
[125I]TGF-L1 ligand internalization assay to further analyze
the ability of mutant TLRIs to form complexes with TLRII
in the presence of TGF-L. As shown in Fig. 5, expression of
TLRII alone resulted in a level of ligand internalization that
was approximately 55% of the level achieved by coexpressing
both wild-type receptors. Similar, low internalization levels
were seen in cells coexpressing TLRII along with D47A,
D98A, K102A or E104A mutant TLRIs. In contrast, coex-
pression of either K39A or K87A mutant TLRIs with TLRII
resulted in internalization levels comparable to that achieved
by coexpression of wild-type TLRI and TLRII. These results
parallel those obtained in the signaling assay and indicate that
the D47A, D98A, K102A and E104A single point mutations
in the TLRI-ECD impair the functionality of the TLRI/TLRII
complex with respect to both ligand-dependent signaling and
ligand internalization.
3.4. Structure^function relationship analysis of TLRI
Structural mapping of functional sites can provide insights
into the mechanisms underlying protein function at the mo-
lecular level. The three-dimensional atomic structure of TLRI-
ECD has not been determined yet. Recently, the crystal struc-
ture of a close homolog of TLRI-ECD, the type IA bone
morphogenetic protein receptor ectodomain (BRIA-ECD)
has been determined in complex with the BMP-2 ligand [21].
In an earlier study [33], a model of TLRI-ECD has been
constructed by homology to protectin (CD59) and re¢ned
by a molecular dynamics simulation (PDB entry 1TBI).
Here we built a homology model of TLRI-ECD based on
the BRIA-ECD structure as a more suitable template in com-
parison with CD59, and re¢ned the conformation of three
non-homologous loop regions using the Monte Carlo sam-
pling with energy minimization (MCM) approach [26^29].
The folding topology stabilized by ¢ve disul¢de bridges of
the TLRI-ECD model is conserved with respect to BRIA-
ECD structure [21] (Fig. 6). The region of high structural
similarity includes the two L-sheets of the domain (formed
by ¢ve L-strands) as well as most of the C-terminal stretch
of residues. The short K-helix that £anks the central L-sheet is
slightly distorted in the TLRI-ECD model as compared with
the BRIA-ECD structure, due to proline residues in this re-
gion of TLRI-ECD. Lower structural similarity is observed
for two of the non-homologous loops included in the MCM
SR (SR-I: loop L1-L2 and SR-III: loop L4-K1), for the loop
K1-L5, as well as for the C-terminal four amino acid residues.
Overall, the modeled TLRI-ECD structure preserves the ‘open
left hand’ topology of the BRIA-ECD structure, with a con-
cave face and a convex face stemming from the curvature of
the central L-sheet.
Mapping of the TLRI residues investigated by mutagenesis
in this study onto the modeled structure of TLRI-ECD is
shown in Fig. 6. All these residues are exposed at the molec-
ular surface, thus suggesting that no major conformational
changes would result upon their individual mutation to ala-
nine. This is in agreement with the wild-type levels of cell
surface expression observed for the corresponding mutant
TLRIs. Residues D47, D98, K102 and E104, which are im-
portant for signaling and ligand internalization correspond to
structurally conserved regions between the TLRI-ECD model
and the BRIA-ECD structure template. These residues are
located close to each other on the convex face of the modeled
TLRI-ECD structure. In contrast, residues K39 and K87
which are not important for signaling and ligand internaliza-
tion, are located at the outer edge of the ectodomain struc-
ture, between its convex and concave faces. The residue K39
belongs to the loop L1-L2, which was included in the MCM
SR (SR-I) and which occupies a more distal position relative
to the corresponding, 3-residue longer loop in the BRIA-ECD
structure. The residue K87 in the loop K1-L5 was positioned
closer to the central L-sheet during model re¢nement and thus
deviates slightly from the location of the equivalent lysine
residue in the BRIA-ECD structure.
The overlap between structural and functional clustering
indicates the presence of a functional epitope on the convex
face of the TLRI-ECD. As demonstrated by our a⁄nity cross-
linking experiments, this functional epitope is not involved in
ligand binding. Our ligand-dependent signaling and ligand
internalization data indicate that this functional epitope of
TLRI is implicated in the stability of the productive TLRI/
TLRII heteromeric complex and thus, it represents a putative
interacting site with the TLRII-ECD. The location of this
TLRII-ECD interacting site on the convex face of TLRI-
ECD is consistent with a model in which the TLRI-ECD/li-
gand interaction would be homologous to the observed
BRIA-ECD/ligand interaction [21], which occurs on the con-
cave face of the ectodomain. In Fig. 6 we displayed the posi-
tion of the BMP-2 ligand dimer relative to the superimposed
ectodomains of TLRI and BRIA. In this putative binding
mode, the functional epitope that we have identi¢ed on the
TLRI-ECD would not interact with the TGF-L ligand and
would be readily available for interaction with TLRII-ECD.
As an additional support for this binding mode is the relative
positioning of this functional epitope on the TLRI-ECD with
respect to the tip of the hairpin L7^L8 of the ligand. In the
case of the TGF-L ligand, this hairpin has been shown to
form an interacting site with TLRII [34]. Both the ligand
site and the TLRI-ECD site could simultaneously contact
the ectodomain of TLRII (Fig. 6). It is possible that some
other residues of TLRI located on the convex face of the
ectodomain and adjacent to those identi¢ed here, would con-
tribute to a larger contact interface with TLRII-ECD.
It is worth noting that the K87A mutation resulted in a
40% reduction of TLRI cross-linking to the ligand. In the
binding mode proposed in Fig. 6, the K87 side chain would
be positioned in close proximity to the ligand, but only par-
tially buried upon complex formation. This suggests that the
K87 side chain of TLRI could be readily employed in the
covalent cross-linking to the TGF-L1 ligand (e.g. with K26,
K31 or K37). Therefore, the decrease in cross-linking e⁄-
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ciency upon K87A mutation could be due to the loss of a free
amino group required for the covalent cross-linking. Based on
the putative binding mode, it is less probable that the K87A
mutation would impair signi¢cantly the TLRI-ECD/ligand in-
teraction in the functional heteromeric receptor complex.
These hypotheses are fully supported by our ligand-dependent
signaling and ligand internalization data, which show a func-
tionally competent K87A mutant TLRI.
Since TGF-L signaling requires ligand stimulation, it is
likely that the inter-receptor binding a⁄nity in the productive
TLRI-ECD/TLRII-ECD complex, in the absence of the li-
gand, is weak. This is consistent with our ¢nding of a receptor
interacting site formed by charged residues, in which case the
intermolecular electrostatic attraction in the complex would
be largely o¡set by the competing desolvation costs incurred
upon binding [35,36]. Thus, the residues in the functional epi-
tope of the TLRI-ECD might not contribute strongly to the
net binding a⁄nity to TLRII-ECD. Their mutation to alanine,
however, would result in sub-optimal electrostatic comple-
mentarity in the complex and therefore, in a considerable
weakening of the net binding a⁄nity due to under-compen-
sated desolvation penalties [37^39]. Given that TGF-L has a
low a⁄nity for TLRI and high a⁄nity for TLRII [6,7], an
e¡ective binding of TLRI-ECD to a preformed TLRII-ECD/
ligand complex could be achieved upon burial of two large
surface, weak a⁄nity interacting sites of TLRI-ECD: one on
its concave face for binding to the ligand, and the other one
on its the convex face for binding to the TLRII-ECD.
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